Search Results - "Provan, S. A."

A validation of register-derived diagnoses of interstitial lung disease in patients with inflammatory arthritis: data from the NOR-DMARD study by Provan, S A, Ahlfors, F, Bakland, G, Hu, Y, Kristianslund, E K, Ikdahl, E, Kvien, T K, Aaløkken, T M, Hoffmann-Vold, A M

“…There is a lack of knowledge concerning the validity of the interstitial lung disease (ILD) diagnoses used in epidemiological studies on rheumatic diseases…”
Get full text

High-intensity cardiorespiratory and strength exercises reduced emotional distress and fatigue in patients with axial spondyloarthritis: a randomized controlled pilot study by Sveaas, SH, Berg, IJ, Fongen, C, Provan, SA, Dagfinrud, H

“…Objective: To investigate the effect of high-intensity exercise on emotional distress, fatigue, and ability to do a full day's activities in patients with…”
Get full text

Circulating levels of inflammatory cytokines and cytokine receptors in patients with ankylosing spondylitis: a cross-sectional comparative study by Sveaas, SH, Berg, IJ, Provan, SA, Semb, AG, Olsen, IC, Ueland, T, Aukrust, P, Vøllestad, N, Hagen, KB, Kvien, TK, Dagfinrud, H

“…Objectives: Insight into the most important inflammatory pathways in ankylosing spondylitis (AS) could be of importance in risk stratification and the…”
Get full text

Biological treatment in ankylosing spondylitis in the Nordic countries during 2010-2016: a collaboration between five biological registries by Glintborg, B, Lindström, U, Aaltonen, K, Kristianslund, EK, Gudbjornsson, B, Chatzidionysiou, K, Askling, J, Nordström, D, Hetland, ML, Di Giuseppe, D, Dreyer, L, Kristensen, LE, Jørgensen, TS, Eklund, K, Grondal, G, Ernestam, S, Joensuu, J, Törmänen, MRK, Skydsgaard, H, Hagfors, J, Kvien, TK, Lie, E, Fagerli, K, Geirsson, AJ, Jonsson, H, Provan, SA, Krogh, NS, Jacobsson, LTH

“…Objectives: Large-scale observational cohorts may be used to study the effectiveness and rare side effects of biological disease-modifying anti-rheumatic drugs…”
Get full text

Biomarkers of cardiovascular risk across phenotypes of osteoarthritis by Provan, S A, Rollefstad, S, Ikdahl, E, Mathiessen, A, Berg, I J, Eeg, I, Wilkinson, I B, McEniery, C M, Kvien, T K, Hammer, H B, Østerås, N, Haugen, I K, Semb, A G

“…The objective of this study was to explore the associations between ultrasonographic and radiographic joint scores and levels of arterial CVD risk markers in…”
Get full text

Uptake and effectiveness of newer biologic and targeted synthetic disease-modifying antirheumatic drugs in psoriatic arthritis: results from five Nordic biologics registries by Glintborg, Bente, Di Giuseppe, Daniela, Wallman, Johan Karlsson, Nordström, Dan C, Gudbjornsson, Bjorn, Hetland, Merete Lund, Askling, Johan, Grondal, Gerdur, Sokka, Tuulikki, Provan, Sella A, Michelsen, Brigitte, Kristianslund, Eirik Klami, Dreyer, Lene, Love, Thorvardur Jon, Lindström, Ulf

“…We aimed to describe the uptake of newer biologic or targeted synthetic disease-modifying antirheumatic drugs (b/tsDMARDs) in psoriatic arthritis (PsA) in the…”
Get more information

Is the risk of infection higher during treatment with secukinumab than with TNF inhibitors? An observational study from the Nordic countries by Glintborg, Bente, Di Giuseppe, Daniela, Wallman, Johan K, Provan, Sella A, Nordström, Dan, Hokkanen, Anna-Mari, Österlund, Jenny, Kristianslund, Eirik, Kvien, Tore K, Gudbjornsson, Bjorn, Hetland, Merete Lund, Michelsen, Brigitte, Jacobsson, Lennart, Askling, Johan, Lindström, Ulf

“…The positioning of secukinumab in the treatment of axial SpA (axSpA) and PsA is debated, partly due to a limited understanding of the comparative safety of the…”
Get full text

Comparison of treatment retention and response to secukinumab versus tumour necrosis factor inhibitors in psoriatic arthritis by Lindström, Ulf, Glintborg, Bente, Di Giuseppe, Daniela, Schjødt Jørgensen, Tanja, Gudbjornsson, Bjorn, Lederballe Grøn, Kathrine, Aarrestad Provan, Sella, Michelsen, Brigitte, Lund Hetland, Merete, Wallman, Johan K, Nordström, Dan, Trokovic, Nina, Love, Thorvardur Jon, Krogh, Niels Steen, Askling, Johan, Jacobsson, Lennart T H, Kristensen, Lars Erik

“…To compare treatment retention and response to secukinumab vs adalimumab, including the other four TNF inhibitors (TNFi) as comparators, in PsA. All patients…”
Get full text

Remission is the goal for cardiovascular risk management in patients with rheumatoid arthritis: a cross-sectional comparative study by Provan, Sella A, Semb, Anne Grete, Hisdal, Jonny, Stranden, Einar, Agewall, Stefan, Dagfinrud, Hanne, Angel, Kristin, Atar, Dan, Kvien, Tore K

“…To compare markers of cardiovascular disease (CVD) risk between patients with rheumatoid arthritis (RA) in an active disease state and those with RA in…”
Get more information

Effectiveness of a second biologic after failure of a non-tumor necrosis factor inhibitor as first biologic in rheumatoid arthritis by Chatzidionysiou, Katerina, Hetland, Merete Lund, Frisell, Thomas, Di Giuseppe, Daniela, Hellgren, Karin, Glintborg, Bente, Nordström, Dan, Peltomaa, Ritva, Aaltonen, Kalle, Trokovic, Nina, Kristianslund, Eirik K, Kvien, Tore K, Provan, Sella A, Gudbjornsson, Bjorn, Grondal, Gerdur, Dreyer, Lene, Kristensen, Lars Erik, Jørgensen, Tanja Schjødt, Jacobsson, Lennart T H, Askling, Johan

“…In Rheumatoid Arthritis (RA), evidence regarding the effectiveness of a second biologic Disease Modifying Anti-Rheumatic Drugs (bDMARDs) in patients whose…”
Get full text

Inflammatory hallmarks of lesser prominence in psoriatic arthritis patients starting biologics: a Nordic population-based cohort study by Lund Hansen, Rebekka, Schoedt Jørgensen, Tanja, Dreyer, Lene, Hetland, Merete L, Glintborg, Bente, Askling, Johan, Di Giuseppe, Daniela, Jacobsson, Lennart T H, Wallman, Johan K, Nordstrom, Dan, Aaltonen, Kalle, Kristianslund, Eirik K, Kvien, Tore K, Provan, Sella A, Gudbjornsson, Bjorn, Love, Thorvadur J, Kristensen, L E

“…Abstract Objectives To assess secular trends in baseline characteristics of PsA patients initiating their first or subsequent biologic DMARD (bDMARD) therapy…”
Get full text

Treatment retention of infliximab and etanercept originators versus their corresponding biosimilars: Nordic collaborative observational study of 2334 biologics naïve patients with spondyloarthritis by Lindström, Ulf, Glintborg, Bente, Di Giuseppe, Daniela, Nordström, Dan, Aarrestad Provan, Sella, Gudbjornsson, Bjorn, Askling, Johan, Lund Hetland, Merete, Aaltonen, Kalle, Krogh, Niels Steen, Geirsson, Arni Jon, Jacobsson, Lennart T H

“…ObjectiveAlthough clinical trials support equivalence of originator products and biosimilars for etanercept and infliximab, real-world studies among…”
Get full text

P4.02: Baseline Crp But Not Nsaid-Use Predicts Future Increased Arterial Stiffness in Ankylosing Spondylitis: Results after 5-Year Follow Up by Berg, I. J., Semb, A. G., van der Heijde, D., Kvien, T. K., Dagfinrud, H., Provan, S. A.

“…Objective Patients with ankylosing spondylitis (AS) have an increased risk of CVD, but previous studies have not shown a worsened risk profile regarding…”
Get full text

P5.14: High Intensity Aerobic Exercise in Patients with Ankylosing Spondylitis Reduces Arterial Stiffness: Results From a Randomized Controlled Trial by Berg, I. J., Semb, A. G., Halvorsen, S., Fongen, C., Kvien, T. K., Dagfinrud, H., Provan, S. A.

“…Objective Patients with ankylosing spondylitis (AS) are at increased risk of CVD. The etiological mechanism or how to reduce risk is not known. Exercise can…”
Get full text

P9.08: The L-Arginine/Asymmetric Dimethylarginine (ADMA) Ratio is Improved During Anti-Tumor Necrosis Factor–Α Therapy in Patients with Inflammatory Arthropathies: Association with Aortic Stiffness by Angel, K., Provan, S. A., Seljeflot, I., Kvien, T. K., Atar, D.

“…Background Anti-Tumor Necrosis Factor (TNF)-α therapy seems to improve cardiovascular risk in patients with inflammatory arthropathies such as rheumatoid…”
Get full text

1.5 Increased Crp Early in the Ra Disease Course Predicts an Increased Risk of Cardiovascular Disease and Arterial Stiffness: 15-Year Follow-Up of the Euridiss Cohort by Provan, S. A., Angel, K., Semb, A. G., Atar, D., Kvien, T. K.

“…Background Patients with rheumatoid arthritis (RA) have increased cardiovascular morbidity and mortality. Objective: To explore whether early markers of RA…”
Get full text

P2.04 Calcium Intake is Independently Associated with Increased Augmentation Index: Results From a Cross-Sectional Follow-Up Study of Two Rheumatoid Arthritis Cohorts by Provan, S. A., Angel, K., Semb, A. G., Atar, D., Kvien, T. K.

“…Background Population studies have indicated that both the presence of osteoporosis and serum levels of calcium are associated with an increased risk of…”
Get full text

P2.03 Early Inflammation Can Predict Arterial Stiffness: A 15-Year Longitudinal Study of 102 Patients with Rheumatoid Arthtritis by Provan, S. A., Angel, K., Semb, A. G., Mowinckel, P., Agewall, S., Atar, D., Kvien, T. K.

“…Objectives To examine impact of early inflammation in RA on the development of CV disease. Methods 238 patients with RA of less than 4 years duration at…”
Get full text

High-Intensity Exercise Improves Fatigue, Sleep, and Mood in Patients With Axial Spondyloarthritis: Secondary Analysis of a Randomized Controlled Trial by Sveaas, Silje Halvorsen, Dagfinrud, Hanne, Berg, Inger Jorid, Provan, Sella Arrestad, Johansen, Melissa Woll, Pedersen, Elisabeth, Bilberg, Annelie

“…Abstract Objective Although exercise is recommended in the treatment of axial spondyloarthritis (axSpa), the focus has been on flexibility, and the effect of…”
Get full text

P2.06 Levels of NT-proBNP are Associated with Arterial Stiffness in Patients with Rheumatoid Arthritis by Provan, S. A., Angel, K., Mowinckel, P., Agewall, S., Atar, D., Kvien, T. K.

“…Background We wished to investigate the association between arterial stiffness and NT-proBNP, a biomarker released in response to atrial and ventricular…”
Get full text